Australia markets closed

Cadrenal Therapeutics, Inc. (CVKD)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4844-0.0156 (-3.12%)
As of 12:21PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.5000
Open0.5000
Bid0.4267 x 900
Ask0.5000 x 1100
Day's range0.4844 - 0.5000
52-week range0.3950 - 6.7500
Volume2,677
Avg. volume46,912
Market cap6.308M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023

    Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, announced today that Quang Pham, CEO, will present at NobleCon19 - Noble Capital Markets' Nineteenth (19) Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in B

  • PR Newswire

    Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update

    Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) ("Cadrenal Therapeutics" or the "Company") a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.

  • PR Newswire

    Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference

    Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, announced today that Quang Pham, CEO, will be participating in a Company Webcast and Panel Presentation at the Lytham Partners Fall 2023 Investor Conference on Tuesday, October 17, 2023. Management will also be c